Open Targets
Annalisa Buniello is an experienced professional in the fields of product management and scientific research, currently serving as a Product Manager at Open Targets since 2022. Prior to this role, Annalisa worked at the European Bioinformatics Institute (EMBL-EBI) from March 2017 to May 2022, holding positions as a Data Scientist (curator) and Scientific Curator. Earlier experience includes a Research Associate role at King's College London, a Postdoctoral Research Fellow position at the Wellcome Trust Sanger Institute, and a Postdoctoral Fellow at EMBL, focusing on sensory neuroscience and learning and memory. Annalisa's academic background includes a degree in Medicinal and Pharmaceutical Chemistry and a PhD in Medical Genetics, both from Università degli Studi di Napoli Federico II.
This person is not in any teams
This person is not in any offices
Open Targets
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. Open Targets brings together complimentary expertise of our academic and industry partners, Bristol Myers Squibb, EMBL-EBI, Genentech, GSK, Pfizer, Wellcome Sanger Institute, and Sanofi. The freely available Open Targets Platform (platform.opentargets.org) makes it easy for researchers working in many disciplines to identify and prioritise therapeutic targets for new medicines. Open Targets Genetics (genetics.opentargets.org), is our portal for investigation of Genome Wide Association Study (GWAS) data to assist in identifying the causal genes to prioritise drug targets. The portal aggregates and merges genetic associations curated from literature and newly-derived loci from UK Biobank andn FinnGen with (open source) functional genomics data including epigenetics (e.g., chromatin conformation, chromatin interactions) and quantitative trait loci (e.g., eQTLs from GTEX, pQTL), and applies statistical fine-mapping across thousands of trait-associated loci, to resolve association signals and link each variant to its proximal and distal target gene(s), using a single evidence score. Open Targets complements data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation, and is committed to sharing its data openly with the scientific community.